Table 1.

Rate of upgrade in patients with pure ADH-BD by core biopsy factors Frequency (percent) reported unless otherwise noted.

	Overall (n = 236)	Upgraded (n = 108)	Not upgraded (n = 128)	p value*
Core needle biopsy diagnosis				0.39
“Reaching/approaching DCIS”	29	11 (10.2)	18 (14.1)
“Bordering on DCIS”	104	50 (46.3)	54 (42.2)
“Suspicious for DCIS”	16	10 (9.3)	6 (4.7)
“Markedly atypical ductal hyperplasia”	87	37 (34.3)	50 (39.1)
Indication for biopsy				< 0.001
Indeterminate calcifications	171	65 (60.2)	106 (82.8)
Mass	52	34 (31.5)	18 (14.1)
Suspicious MRI enhancement	10	6 (5.6)	4 (3.1)
Unknown	3	3 (2.8)	0 (0)
Type of core biopsy				0.001
MR-guided	10	6 (5.6)	4 (3.1)
Stereotactic	155	57 (52.8)	98 (76.6)
Ultrasound-guided	48	32 (29.6)	16 (12.5)
Unknown	23	13 (12.0)	10 (7.8)
Number of core specimens Median (range), n†	8 (1, 31), 74	6 (1, 27), 37	8 (1, 31), 37	0.04
Needle gauge Median (range), n‡	11 (6, 22), 89	11 (8, 14), 46	11 (6, 22), 43	0.27

^*Results from Fisher’s exact test for categorical variables, and the Wilcoxon rank-sum test for continuous variables.

^†Number of core specimens is missing for 67% of the observations.

^‡Needle gauge is missing for 62% of the observations.

ADH-BD atypical ductal hyperplasia bordering on ductal carcinoma in situ, DCIS ductal carcinoma in situ, MR magnetic resonance